Skip to main content
. 2022 Nov 10;13(12):1856–1863. doi: 10.1021/acsmedchemlett.2c00213

Figure 5.

Figure 5

Lazertinib effectively ablates EGFR(L858R/T790M) phosphorylation in NSCLC H1975 cells and marginal inhibition of HER2 in BT474 breast cancer cells. (A) Western blot analysis of phosphorylated EGFR (pY1068) after dose-dependent treatment of H1975 (L858R/T790M) lung adenocarcinoma cell lines with osimertinib, lazertinib, and LN2057 for 2 h. (B) Western blot analysis of phosphorylated HER2 (pY1221/1222) after dose-dependent treatment of BT474 breast cancer cells with osimertinib, lazertinib, and LN2057 for 6 h. Western blots are representative examples of three independent experiments.